Status Report on HIV Drug Treatment Transition from Tenofovir/Lamivudine/Efavirenz (TLE 600mg) to Tenofovir/Lamivudine/Dolutegravir (TLD) in Malawi

The Malawi Antiretroviral therapy (ART) program has over 740,000 patients on ART by end of September, 2017. This represents 71% of the estimated 1,036,000 HIV positive population [1]. In December 2017, the Ministry of Health (MoH) in Malawi made a decision to adopt a new drug combination which is Tenofovir/ Lamivudine/ Dolutegravir (TLD) as preferred first-line regimen for ART.